What is Corcept Therapeutics's market cap?

Corcept Therapeutics (CORT) has a market capitalization of $10.1B and trades on NASDAQ.

What is Corcept Therapeutics's revenue and profitability?

Corcept Therapeutics generated $830.8M in trailing twelve-month revenue with net income of $55.2M, representing a net margin of 6.6%. Gross margin stands at 98.3%, with free cash flow of $106.9M. These figures are based on the Q2 2026 filing.

Who are Corcept Therapeutics's competitors?

Corcept Therapeutics's key competitors include Xeris Biopharma Holdings, Inc., Crinetics Pharmaceuticals, Inc., Corbus Pharmaceuticals Holdings, Inc., and others. These companies compete in similar markets and product categories.

Who does Corcept Therapeutics partner with?

Corcept Therapeutics's notable partners include Curant Health Georgia, LLC, Syneos Health, Medpace Research, and others.

Where is Corcept Therapeutics headquartered?

Corcept Therapeutics is headquartered in United States of America and employs approximately 352 people. It has been publicly traded since 2004.

Corcept Therapeutics

CORT

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of medications that modulate the effects of the hormone cortisol.

Market cap

$9.78B+31.9%

Revenue$830.8M+16.0%

Net income$55.2M-58.7%

Free cash flow$106.9M-40.7%

EPS (diluted)$0.42-62.5%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2025 report

July 29, 2026

Revenue$194.4MMiss by $26.7M EPS$0.29Beat by $0.27

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$256.1M+31.7%

Gross profit$252.1M+32.0%

Operating income$41.3M+54.8%

Net income$43.0M+22.3%

EPS (diluted)$0.36+24.1%

Balance sheet

See full

Cash & equivalents$112.3M+9.3%

Total debt$9.4M+42.6%

Total equity$705.8M+11.0%

Total assets$888.7M+10.8%

Cash flow

See full

Operating cash flow$33.5M-23.7%

CapEx$2.5M+4,335%

Free cash flow$31.0M-29.3%

Valuation & ratios

Valuation

See full

Market cap$9.78B+31.9%

Enterprise value$9.68B+33.7%

P/E177.3×+122×

P/S11.8×+1.5×

Profitability

See full

Gross margin98.3%-0.1pp

Operating margin0.8%-13.5pp

Net margin6.6%-12.0pp

FCF margin12.9%-12.3pp

Returns & leverage

See full

Return on equity8.2%-13.5pp

Debt / equity0×0.0×

Current ratio2.9×-0.2×

Competitors

By market cap

Corcept Therapeutics$9.8B+33.4%

Crinetics Pharmaceuticals$8.9B+213%

XER

Xeris Biopharma Holdings, Inc.$1.4B+74.6%

Cullinan Therapeutics, Inc.$1.1B+121%

Coherus BioSciences$225.2M+81.5%

Corbus Pharmaceuticals$168.2M+43.4%

SPR

Spruce Biosciences, Inc. $115.6M—

Oncolytics Biotech, Inc.$95.5M-9.3%

By revenue growth

Crinetics Pharmaceuticals+2,278%

XER

Xeris Biopharma Holdings, Inc.+41.5%

Corcept Therapeutics+16.0%

By net margin

Corcept Therapeutics6.64%-12.0pp

XER

Xeris Biopharma Holdings, Inc.3.81%+24.1pp

Cullinan Therapeutics, Inc.-346.14%—

Crinetics Pharmaceuticals-2,747.18%+40,444pp

Profile

Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of medications that modulate the effects of the hormone cortisol. The company leverages its proprietary portfolio of selective cortisol modulators to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its primary value proposition lies in managing hypercortisolism and improving outcomes in various solid tumors and neuromuscular diseases without the adverse effects associated with traditional progesterone receptor binding.

Competitive position

A leading specialist in cortisol modulation with a significant proprietary library of over 1,000 selective cortisol modulators and a commercial presence in the Cushing's syndrome market.

GeographiesUnited States, European Union

Customer segmentsPatients, Healthcare Providers

Business modelResearch and Development, Product Sales

SuppliersContract Manufacturing Organizations (CMOs), Clinical Research Organizations (CROs), Active Pharmaceutical Ingredient (API) Suppliers

CustomersSpecialty Pharmacies, Specialty Distributors, Hospitals, Physicians

CountryUnited States of America

Listed2004

Employees352.0

CEOJoseph K. Belanoff

SectorHealthcare

IndustryBiotechnology

Websitecorcept.com

FilingsSEC EDGAR

Ask your AI about Corcept Therapeutics.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Corcept Therapeutics's market cap?: Corcept Therapeutics (CORT) has a market capitalization of $10.1B and trades on NASDAQ.
What is Corcept Therapeutics's revenue and profitability?: Corcept Therapeutics generated $830.8M in trailing twelve-month revenue with net income of $55.2M, representing a net margin of 6.6%. Gross margin stands at 98.3%, with free cash flow of $106.9M. These figures are based on the Q2 2026 filing.
Who are Corcept Therapeutics's competitors?: Corcept Therapeutics's key competitors include Xeris Biopharma Holdings, Inc., Crinetics Pharmaceuticals, Inc., Corbus Pharmaceuticals Holdings, Inc., and others. These companies compete in similar markets and product categories.
Who does Corcept Therapeutics partner with?: Corcept Therapeutics's notable partners include Curant Health Georgia, LLC, Syneos Health, Medpace Research, and others.
Where is Corcept Therapeutics headquartered?: Corcept Therapeutics is headquartered in United States of America and employs approximately 352 people. It has been publicly traded since 2004.